Lipoprotein (a) Level is Associated with Plaque Vulnerability in Patients with Coronary Artery Disease: An Optical Coherence Tomography Study

Overview

Journal Int J Cardiol Heart Vasc

Date 2019 Jun 28

PMID 31245530

Citations 15

Authors

Yusuke Muramatsu

Yoshiyasu Minami

Ayami Kato

Aritomo Katsura

Toshimitsu Sato

Ryota Kakizaki

Teruyoshi Nemoto

Takuya Hashimoto

Kazuhiro Fujiyoshi

Kentaro Meguro

Takao Shimohama

Junya Ako

Affiliations

Soon will be listed here.

Abstract

Background: High lipoprotein (a) [Lp(a)] levels are an independent factor for worse prognosis in patients with coronary artery disease (CAD). However, the association between serum Lp(a) level and coronary plaque vulnerability remains to be determined.

Methods: A total of 255 consecutive patients with CAD who underwent optical coherence tomography imaging of culprit lesions were included. Patients were divided into 2 groups according to their Lp(a) levels (the higher Lp(a) group [≥25 mg/dL],  = 87; or the lower Lp(a) group [<25 mg/dL],  = 168).

Results: The prevalence of thin-cap fibroatheroma (TCFA) was significantly higher in the higher Lp(a) group than in the lower Lp(a) group (23% [ = 20] vs. 11% [ = 19],  = 0.014). Although the prevalence of TCFA was comparable between the 2 groups among patients with a lower LDL cholesterol (LDL-C) level (<100 mg/dL), TCFA was significantly more prevalent in the higher Lp(a) group than in the lower Lp(a) group (39% [14/36] vs. 10% [5/50],  = 0.001) among patients with a higher LDL-C level (≥100 mg/dL).

Conclusions: A higher Lp(a) level was associated with a higher frequency of TCFA, particularly in patients with a higher LDL-C level.

Citing Articles

The Role of Cardiac Computed Tomography Angiography in Risk Stratification for Coronary Artery Disease.

van Rosendael S, Shiyovich A, Cardoso R, Souza Freire C, van Rosendael A, Lin F J Soc Cardiovasc Angiogr Interv. 2024; 3(11):102230.

PMID: 39649823 PMC: 11624369. DOI: 10.1016/j.jscai.2024.102230.

Association Between Lipoprotein(a) and Obstructive Coronary Artery Disease and High-Risk Plaque: Insights From the PROMISE Trial.

OToole T, Shah N, Giamberardino S, Kwee L, Voora D, McGarrah R Am J Cardiol. 2024; 231:40-47.

PMID: 39245334 PMC: 11524762. DOI: 10.1016/j.amjcard.2024.09.006.

Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects-A Pilot Study.

Hachula M, Kosowski M, Basiak M, Okopien B Medicina (Kaunas). 2024; 60(6).

PMID: 38929525 PMC: 11205508. DOI: 10.3390/medicina60060908.

High lipoprotein(a): Actionable strategies for risk assessment and mitigation.

Reyes-Soffer G, Yeang C, Michos E, Boatwright W, Ballantyne C Am J Prev Cardiol. 2024; 18:100651.

PMID: 38646021 PMC: 11031736. DOI: 10.1016/j.ajpc.2024.100651.

The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients.

Wang X, Chen X, Wang Y, Peng S, Pi J, Yue J Int J Gen Med. 2023; 16:2805-2817.

PMID: 37426518 PMC: 10328105. DOI: 10.2147/IJGM.S410840.

References

Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D . Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J. 2006; 28(8):961-7. DOI: 10.1093/eurheartj/ehl413. View

Willeit P, Ridker P, Nestel P, Simes J, Tonkin A, Pedersen T . Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018; 392(10155):1311-1320. DOI: 10.1016/S0140-6736(18)31652-0. View

Kato K, Yonetsu T, Kim S, Xing L, Lee H, McNulty I . Nonculprit plaques in patients with acute coronary syndromes have more vulnerable features compared with those with non-acute coronary syndromes: a 3-vessel optical coherence tomography study. Circ Cardiovasc Imaging. 2012; 5(4):433-40. DOI: 10.1161/CIRCIMAGING.112.973701. View

Niccoli G, Cin D, Scalone G, Panebianco M, Abbolito S, Cosentino N . Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. Atherosclerosis. 2016; 246:214-20. DOI: 10.1016/j.atherosclerosis.2016.01.020. View

Nordestgaard B, Chapman M, Humphries S, Ginsberg H, Masana L, Descamps O . Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34(45):3478-90a. PMC: 3844152. DOI: 10.1093/eurheartj/eht273. View

Nordestgaard B, Chapman M, Ray K, Boren J, Andreotti F, Watts G . Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31(23):2844-53. PMC: 3295201. DOI: 10.1093/eurheartj/ehq386. View

Yonetsu T, Kakuta T, Lee T, Takahashi K, Kawaguchi N, Yamamoto G . In vivo critical fibrous cap thickness for rupture-prone coronary plaques assessed by optical coherence tomography. Eur Heart J. 2011; 32(10):1251-9. DOI: 10.1093/eurheartj/ehq518. View

Tsimikas S . A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017; 69(6):692-711. DOI: 10.1016/j.jacc.2016.11.042. View

Kral B, Kalyani R, Yanek L, Vaidya D, Fishman E, Becker D . Relation of Plasma Lipoprotein(a) to Subclinical Coronary Plaque Volumes, Three-Vessel and Left Main Coronary Disease, and Severe Coronary Stenoses in Apparently Healthy African-Americans With a Family History of Early-Onset Coronary Artery Disease. Am J Cardiol. 2016; 118(5):656-61. PMC: 4991623. DOI: 10.1016/j.amjcard.2016.06.020. View

10.

Tearney G, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra H . Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol. 2012; 59(12):1058-72. DOI: 10.1016/j.jacc.2011.09.079. View

11.

Dahlen G, Guyton J, Attar M, Farmer J, Kautz J, Gotto Jr A . Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986; 74(4):758-65. DOI: 10.1161/01.cir.74.4.758. View

12.

Erqou S, Kaptoge S, Perry P, Di Angelantonio E, Thompson A, White I . Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302(4):412-23. PMC: 3272390. DOI: 10.1001/jama.2009.1063. View

13.

Minami Y, Wang Z, Aguirre A, Ong D, Kim C, Uemura S . Clinical Predictors for Lack of Favorable Vascular Response to Statin Therapy in Patients With Coronary Artery Disease: A Serial Optical Coherence Tomography Study. J Am Heart Assoc. 2017; 6(11). PMC: 5721742. DOI: 10.1161/JAHA.117.006241. View

14.

Kostner K, Kostner G, Wierzbicki A . Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate. Atherosclerosis. 2018; 274:16-22. DOI: 10.1016/j.atherosclerosis.2018.04.032. View

15.

ODonoghue M, Fazio S, Giugliano R, Stroes E, Kanevsky E, Gouni-Berthold I . Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2018; 139(12):1483-1492. DOI: 10.1161/CIRCULATIONAHA.118.037184. View

16.

Di Vito L, Yoon J, Kato K, Yonetsu T, Vergallo R, Costa M . Comprehensive overview of definitions for optical coherence tomography-based plaque and stent analyses. Coron Artery Dis. 2013; 25(2):172-85. DOI: 10.1097/MCA.0000000000000072. View

17.

Chieng D, Pang J, Ellis K, Hillis G, Watts G, Schultz C . Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease. J Clin Lipidol. 2018; 12(4):1019-1026. DOI: 10.1016/j.jacl.2018.03.090. View

18.

Cook N, Mora S, Ridker P . Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. J Am Coll Cardiol. 2018; 72(3):287-296. PMC: 6277983. DOI: 10.1016/j.jacc.2018.04.060. View

19.

Kitabata H, Tanaka A, Kubo T, Takarada S, Kashiwagi M, Tsujioka H . Relation of microchannel structure identified by optical coherence tomography to plaque vulnerability in patients with coronary artery disease. Am J Cardiol. 2010; 105(12):1673-8. DOI: 10.1016/j.amjcard.2010.01.346. View

20.

Takarada S, Imanishi T, Ishibashi K, Tanimoto T, Komukai K, Ino Y . The effect of lipid and inflammatory profiles on the morphological changes of lipid-rich plaques in patients with non-ST-segment elevated acute coronary syndrome: follow-up study by optical coherence tomography and intravascular ultrasound. JACC Cardiovasc Interv. 2010; 3(7):766-72. DOI: 10.1016/j.jcin.2010.05.001. View